Evidence map›Paper›PMID 39487884›Full record

ArticleClinical and experimental nephrology2025

Kidney injury associated with fosravuconazole L-lysine ethanolate.

Takahiro Shinzato, Kojiro Nagai, Yuuki Hoshino, Yuuichi Fujiwara, Yoshihiro Yamamoto, Kikuno Ogura, Azusa Morishita, Takao Okawa, Kenta Ito, Masaaki Murakami and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Takahiro ShinzatoDepartment of Nephrology, Shizuoka General Hospital, 4-21-1, Kitaando, Aoi Ward, Shizuoka City, Shizuoka, 4208527, Japan. shinzatotakahiro@gmail.com.ORCID http://orcid.org/0000-0001-5705-7612
Kojiro NagaiDepartment of Nephrology, Shizuoka General Hospital, 4-21-1, Kitaando, Aoi Ward, Shizuoka City, Shizuoka, 4208527, Japan.
Yuuki HoshinoDepartment of Nephrology, Shizuoka General Hospital, 4-21-1, Kitaando, Aoi Ward, Shizuoka City, Shizuoka, 4208527, Japan.
Yuuichi FujiwaraDepartment of Nephrology, Shizuoka General Hospital, 4-21-1, Kitaando, Aoi Ward, Shizuoka City, Shizuoka, 4208527, Japan.
Yoshihiro YamamotoDepartment of Nephrology, Shizuoka General Hospital, 4-21-1, Kitaando, Aoi Ward, Shizuoka City, Shizuoka, 4208527, Japan.
Kikuno OguraDepartment of Nephrology, Shizuoka General Hospital, 4-21-1, Kitaando, Aoi Ward, Shizuoka City, Shizuoka, 4208527, Japan.
Azusa MorishitaDepartment of Nephrology, Shizuoka General Hospital, 4-21-1, Kitaando, Aoi Ward, Shizuoka City, Shizuoka, 4208527, Japan.
Takao OkawaDepartment of Nephrology, Shizuoka General Hospital, 4-21-1, Kitaando, Aoi Ward, Shizuoka City, Shizuoka, 4208527, Japan.
Kenta ItoDepartment of Nephrology, Shizuoka General Hospital, 4-21-1, Kitaando, Aoi Ward, Shizuoka City, Shizuoka, 4208527, Japan.
Masaaki MurakamiDepartment of Nephrology, Shizuoka General Hospital, 4-21-1, Kitaando, Aoi Ward, Shizuoka City, Shizuoka, 4208527, Japan.
Ken MatsuoDepartment of Nephrology, Shizuoka General Hospital, 4-21-1, Kitaando, Aoi Ward, Shizuoka City, Shizuoka, 4208527, Japan.
Satoshi TanakaDepartment of Nephrology, Shizuoka General Hospital, 4-21-1, Kitaando, Aoi Ward, Shizuoka City, Shizuoka, 4208527, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFosravuconazole L-lysine ethanolate (F-RVCZ) is a prodrug of ravuconazole and a triazole antifungal drug used for the treatment of onychomycosis. It has been reported in previous studies that the kidney injury caused by F-RVCZ is 1% or less.

methodsSerum creatinine levels were compared, and glomerular filtration rate and urine protein were estimated before and after starting the administration of F-RVCZ, as well as after the end of the administration period. The cause of kidney injury was investigated using renal pathology, and risk factors were also investigated.

resultsF-RVCZ was administered to 46 patients. Ten of these patients were excluded because three were maintenance dialysis patients and seven were not measured for serum creatinine. Remaining 36 patients were included in the analyses. Kidney injury occurred in 27.8% of patients treated with F-RVCZ; this condition persisted in 10% of patients after the end of the administration period. No changes were observed in the urinalysis after the administration of F-RVCZ. A kidney biopsy was performed in one patient, but no lesions were found that could be the cause of kidney injury. Patients who developed kidney injury were significantly more likely to be receiving angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (odds ratio 18.9, 95% confidential interval: 1.69-210, p = 0.0169).

conclusionKidney injury is caused by F-RVCZ more frequently than previously reported, but the mechanism remains unclear.

Indexed as

Acute Kidney InjuryAntifungal AgentsKidneyLysineTriazolesAdultAgedBiomarkersCreatinineFemaleGlomerular Filtration RateHumansMaleMiddle AgedProteinuriaRisk FactorsAntifungal AgentsBiomarkersCreatinineLysineTriazolesDrug-induced kidney injuryFosravuconazole l-lysine ethanolateOnychomycosis

Identifiers

PMID39487884

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.